Methylene Blue: Mechanism, Dosing, and Safety

Methylene blue (tetramethylthionine chloride) is an electron carrier that supports mitochondrial respiration by recycling electrons within the electron transport chain.

I have written a book on this compound and I use it in clinical practice. So I want to lead with the thing most people selling it will not tell you.

Who should not take methylene blue?

Methylene blue is a reversible MAO-A inhibitor. That single fact defines its safety profile, and it is the first thing you need to know, not the last.

Absolute contraindications: serotonergic medications, including SSRIs, SNRIs, tricyclic antidepressants, triptans, tramadol and meperidine. Because methylene blue inhibits MAO-A, combining it with these drugs carries a risk of serotonin syndrome, which can be fatal. The FDA has issued a formal warning on this combination.

Irreversible MAOIs, including phenelzine, tranylcypromine and selegiline: never combine. This is not a risk to be weighed; it is a line not to cross.

G6PD deficiency: risk of hemolysis. Pregnancy.

If you take an antidepressant, you should not take methylene blue. I want that sentence to be unambiguous, because I have watched people get this wrong.

And to be equally clear about the corollary: do not come off your antidepressant in order to take methylene blue without direct medical supervision. Antidepressant discontinuation carries its own serious risks. Trading a managed medication for an unsupervised experiment is not a good trade.

Serotonin syndrome presents with mental status changes, muscle twitching, excessive sweating, shivering or tremor, diarrhea, impaired coordination, and fever. Onset is typically within the first 48 to 72 hours. If you experience these, seek medical attention immediately.

Is the FDA warning overstated? An honest look at the dose question

There is a legitimate scientific argument that the serotonin syndrome risk is dose-dependent, and it deserves to be stated accurately rather than either amplified or dismissed.

Professor Francisco Gonzalez-Lima, one of the principal researchers on methylene blue's neurometabolic effects, has argued that the FDA warning derived largely from a small number of surgical cases: patients undergoing procedures while taking SSRIs, who received methylene blue intravenously at doses of roughly 3 to 7 mg/kg. He has argued that substantially lower oral doses represent a different pharmacological situation.

That argument has real merit and I think it is worth understanding. But here is what it does not license.

MAO-A inhibition by methylene blue is dose-dependent. It is not zero at low doses. Lower risk is not no risk. The clinical case reports exist. And a person reading this page is not a supervised patient with a clinician monitoring them; they are someone who may take more than intended, may not disclose a medication, or may combine it with something I have not anticipated.

So my position, stated plainly: the dose distinction is scientifically real, and I still will not recommend methylene blue to anyone on a serotonergic medication. The asymmetry decides it. If I am overcautious, you miss a supplement. If I am undercautious, someone dies. That is not a close call.

How does methylene blue work?

Methylene blue is an electron carrier, and to understand why that matters you need to understand how a cell makes energy.

Your mitochondria convert glucose and oxygen into energy through the electron transport chain. Electrons are passed down a series of complexes, releasing the chemical energy the cell uses to make ATP, the energy currency of every cell in your body.

Methylene blue can both accept and donate electrons within that chain. It recycles them. When the chain is impaired, by toxins, by inflammation, by age, methylene blue can carry electrons across the gap, supporting respiration that would otherwise stall.

The practical consequence is that it encourages cellular oxygen consumption and decreases anaerobic glycolysis. That second part matters more than it sounds. Under stress, cells abandon the electron transport chain and fall back on glycolysis, a primitive emergency pathway that produces roughly 10 percent of the energy the electron transport chain does. A cell stuck in that state is a cell running on fumes. Methylene blue helps pull it back.

This is why methylene blue is a mitochondrial support compound, not a stimulant. It does not push the system harder. It restores a pathway that has failed.

What is the dose of methylene blue?

In my clinical practice I work within a range of 0.5 to 4 mg per kilogram of body weight for oral methylene blue. For a 70 kg adult, that spans roughly 35 mg to 280 mg. Cautious practice begins at the bottom of that range and stays there until there is reason to move.

Three things about that number, all of which matter.

It is not a self-administration instruction. Methylene blue is a pharmacologically active MAO-A inhibitor with hard contraindications. Screening comes before dosing.

Source quality is not optional. Industrial-grade methylene blue contains contaminants including heavy metals. Only pharmaceutical-grade, USP-grade material is appropriate for human use. This is a real hazard, not a marketing point. Do not buy methylene blue from an aquarium shop.

Higher is not better. Methylene blue is hormetic: beneficial at low doses and counterproductive at high ones. At high concentrations it can act as an oxidant rather than supporting respiration. The dose-response curve bends back on itself.

What is methylene blue used for?

Methylene blue's only FDA-approved indication is the treatment of methemoglobinemia. Every other use discussed here, including my own clinical use, is outside that approval, and you are entitled to know that clearly.

It has an unusual history. Discovered in 1870 as an aniline dye for cotton, it was soon found to stain human tissue, and became the first fully synthetic compound used as a medicine, the work that connects it to Paul Ehrlich and the origins of chemotherapy.

Contemporary research interest centres on its mitochondrial and neuroprotective effects. See Tucker, Lu and Zhang, From Mitochondrial Function to Neuroprotection: An Emerging Role for Methylene Blue, Molecular Neurobiology 2018;55(6):5137-5153; and Rojas, Bruchey and Gonzalez-Lima, Neurometabolic Mechanisms for Memory Enhancement and Neuroprotection of Methylene Blue.

In my own practice I use it as an adjunct in biotoxin, mold and Lyme disease cases, and in photobiomodulation, where methylene blue acts as a photodynamic substance amplifying the effect of red and near-infrared light. I also use it alongside high-dose melatonin, on the reasoning that the two support mitochondria by different and complementary mechanisms.

Evidence quality varies substantially across these applications, from reasonably established to frankly preliminary, and I would rather say so than let a web page imply a uniformity that does not exist.

Will methylene blue turn your urine blue? Yes. Blue-green urine is expected and harmless. It is not a sign of anything going wrong.

Dr. John Lieurance is the author of Methylene Blue: Magic Bullet, 3rd edition (ISBN 979-8317049751), which includes bonus material from Dr. Jason Sonners and Brian Richards on combining hyperbaric oxygen, light and methylene blue.

Medical disclaimer. This article is educational and does not constitute medical advice. Methylene blue is FDA-approved only for methemoglobinemia; all other uses discussed are off-label. Doses described reflect clinical practice and are not a recommendation for self-administration. Methylene blue has absolute contraindications including serotonergic medications, MAOIs, G6PD deficiency and pregnancy. Consult a qualified clinician before use. Reviewed by Dr. John Lieurance, DC, ND.

Disclosure: Dr. Lieurance formulates methylene blue products through MitoZen. This commercial relationship is disclosed in the interest of transparency; the clinical information above, including the contraindications, is presented independently of it.